Abstract: The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides Tmax value of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described. The invention also provides a pharmaceutical composition for intranasal administration comprising a triptan, a pharmaceutically acceptable vehicle and a mucosal permeation enhancer, wherein upon said administration said composition provides a Tmax substantially equivalent to subcutaneous administration of said triptan. Other aspects and embodiments are contemplated and described.

Abstract: The present disclosure relates to methods and apparatus for graphics processing. The apparatus can obtain at least one input image including a plurality of pixels. Additionally, the apparatus can determine shading information for each of the plurality of pixels in the at least one input image. The apparatus can also determine a shading map based on the determined shading information for each of the plurality of pixels in the at least one input image. In some aspects, the apparatus can generate at least one output image based on the at least one input image and the determined shading map. The apparatus can also enhance a quality of the at least one output image. In some aspects, the quality of the at least one output image can be enhanced based on machine learning. Further, the apparatus can generate the at least one input image including the plurality of pixels.

Abstract: The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides Tmax value of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described. The invention also provides a pharmaceutical composition for intranasal administration comprising a triptan, a pharmaceutically acceptable vehicle and a mucosal permeation enhancer, wherein upon said administration said composition provides a Tmax substantially equivalent to subcutaneous administration of said triptan. Other aspects and embodiments are contemplated and described.

Abstract: A computer-implemented technique is described herein for using a machine-trained model to identify individual objects within images. The technique then creates a relational index for the identified objects. That is, each index entry in the relational index is associated with a given object, and includes a set of attributes pertaining to the given object. One such attribute identifies at least one latent semantic vector associated with the given object. Each attribute provides a way of linking the given object to one or more other objects in the relational index. In one application of this technique, a user may submit a query that specifies a query object. The technique consults the relational index to find one or more objects that are related to the query object. In some cases, the query object and each of the other objects have a complementary relationship.

Abstract: A computer-implemented technique is described herein for retrieving at least one recommended output image. In one implementation, the technique uses a generator component to transform first-part image information, associated with a first-part image selected by a user, into one or more instances of second-part generated image information. Each instance of the second-part generated image information complements the first-part image information. The generator component is trained by a computer-implemented training system using a conditional generative adversarial network (cGAN). The technique further includes: retrieving one or more second-part output images from a data store based on the instance(s) of second-part generated image information; generating a user interface presentation that presents the first-part image and the second-part output image(s); and displaying the user interface presentation on a display device.

Abstract: The present disclosure relates to methods and apparatus for graphics processing. The apparatus can obtain at least one input image including a plurality of pixels. Additionally, the apparatus can determine shading information for each of the plurality of pixels in the at least one input image. The apparatus can also determine a shading map based on the determined shading information for each of the plurality of pixels in the at least one input image. In some aspects, the apparatus can generate at least one output image based on the at least one input image and the determined shading map. The apparatus can also enhance a quality of the at least one output image. In some aspects, the quality of the at least one output image can be enhanced based on machine learning. Further, the apparatus can generate the at least one input image including the plurality of pixels.

Abstract: A computer-implemented technique is described herein for using a machine-trained model to identify individual objects within images. The technique then creates a relational index for the identified objects. That is, each index entry in the relational index is associated with a given object, and includes a set of attributes pertaining to the given object. One such attribute identifies at least one latent semantic vector associated with the given object. Each attribute provides a way of linking the given object to one or more other objects in the relational index. In one application of this technique, a user may submit a query that specifies a query object. The technique consults the relational index to find one or more objects that are related to the query object. In some cases, the query object and each of the other objects have a complementary relationship.

Abstract: A method, computer program product, and computing system for determining, at the computing device, one or more dependencies associated with a plurality of managed objects and a plurality of backend objects. One or more backend notifications associated with one or more backend objects of the plurality of backend objects may be received. One or more managed objects of the plurality of managed objects associated with the one or more backend objects of the one or more backend notifications may be identified, based upon, at least in part, the one or more dependencies associated with the plurality of managed objects and the plurality of backend objects. The one or more identified managed objects of the plurality of managed objects may be updated based upon, at least in part, the one or more backend notifications.

Abstract: The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides Tmax value of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described. The invention also provides a pharmaceutical composition for intranasal administration comprising a triptan, a pharmaceutically acceptable vehicle and a mucosal permeation enhancer, wherein upon said administration said composition provides a Tmax substantially equivalent to subcutaneous administration of said triptan. Other aspects and embodiments are contemplated and described.

Abstract: A computer-implemented technique is described herein for retrieving at least one recommended output image. In one implementation, the technique uses a generator component to transform first-part image information, associated with a first-part image selected by a user, into one or more instances of second-part generated image information. Each instance of the second-part generated image information complements the first-part image information. The generator component is trained by a computer-implemented training system using a conditional generative adversarial network (cGAN). The technique further includes: retrieving one or more second-part output images from a data store based on the instance(s) of second-part generated image information; generating a user interface presentation that presents the first-part image and the second-part output image(s); and displaying the user interface presentation on a display device.

Abstract: A method, computer program product, and computing system for determining, at the computing device, one or more dependencies associated with a plurality of managed objects and a plurality of backend objects. A plurality of consistency groups with one or more managed objects of the plurality of managed objects and one or more backend objects of the plurality of backend objects may be generated based upon, at least in part, the one or more dependencies associated with the plurality of managed objects and the plurality of backend objects. The one or more backend objects of the plurality of consistency groups may be fetched. The one or more managed objects of the plurality of consistency groups may be updated based upon, at least in part, the one or more fetched backend objects.

Abstract: The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides Tmax value of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described. The invention also provides a pharmaceutical composition for intranasal administration comprising a triptan, a pharmaceutically acceptable vehicle and a mucosal permeation enhancer, wherein upon said administration said composition provides a Tmax substantially equivalent to subcutaneous administration of said triptan. Other aspects and embodiments are contemplated and described.

Abstract: The various embodiments herein provide an insulated container. The container comprises a body assembly and a lid assembly. The body assembly comprises of an outer plastic body and a plastic ring insert molded with an inner stainless steel (SS) container. The inner SS container has a non-woven polyester fabric acting as an insulation material. The non-woven polyester fabric is enclosed in between the outer plastic body and the inner SS container. The lid assembly comprises of a plastic top lid, an inner lid and a bowl with non-woven polyester fabric acting as insulation. The polyester fabric is sandwiched between the plastic top lid, the inner lid and the bowl. In the body assembly, the outer plastic body and the inner plastic ring is joined together using a spin welding technique. In the lid assembly the top lid, inner lid and bowl are joined together using spin welding technique.

Abstract: The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides Tmax value of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described. The invention also provides a pharmaceutical composition for intranasal administration comprising a triptan, a pharmaceutically acceptable vehicle and a mucosal permeation enhancer, wherein upon said administration said composition provides a Tmax substantially equivalent to subcutaneous administration of said triptan. Other aspects and embodiments are contemplated and described.

Abstract: The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides Tmax value of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described. The invention also provides a pharmaceutical composition for intranasal administration comprising a triptan, a pharmaceutically acceptable vehicle and a mucosal permeation enhancer, wherein upon said administration said composition provides a Tmax substantially equivalent to subcutaneous administration of said triptan. Other aspects and embodiments are contemplated and described.

Abstract: The various embodiments herein provide an insulated container. The container comprises a body assembly and a lid assembly. The body assembly comprises of an outer plastic body and a plastic ring insert molded with an inner stainless steel (SS) container. The inner SS container has a non-woven polyester fabric acting as an insulation material. The non-woven polyester fabric is enclosed in between the outer plastic body and the inner SS container. The lid assembly comprises of a plastic top lid, an inner lid and a bowl with non-woven polyester fabric acting as insulation. The polyester fabric is sandwiched between the plastic top lid, the inner lid and the bowl. In the body assembly, the outer plastic body and the inner plastic ring is joined together using a spin welding technique. In the lid assembly the top lid, inner lid and bowl are joined together using spin welding technique.

Abstract: The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides Tmax value of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described. The invention also provides a pharmaceutical composition for intranasal administration comprising a triptan, a pharmaceutically acceptable vehicle and a mucosal permeation enhancer, wherein upon said administration said composition provides a Tmax substantially equivalent to subcutaneous administration of said triptan. Other aspects and embodiments are contemplated and described.

Abstract: The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides Tmax value of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described. The invention also provides a pharmaceutical composition for intranasal administration comprising a triptan, a pharmaceutically acceptable vehicle and a mucosal permeation enhancer, wherein upon said administration said composition provides a Tmax substantially equivalent to subcutaneous administration of said triptan. Other aspects and embodiments are contemplated and described.

Abstract: The present application discloses a pharmaceutical composition comprising a class of CETP inhibitors with improved oral bioavailability. The application further discloses compositions comprising a class of CETP inhibitor and at least one solubility improving material and optionally one or more wetting agents.